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Importance of geranylgeranyl pyrophosphate for mesangial studies have demonstrated the presence of low molecular
cell DNA synthesis. weight G proteins in glomerular mesangial cells [3, 4].
Background. Farnesyl pyrophosphate (FPP) and geranyl- Much experimental and clinical evidence suggests that
geranyl pyrophosphate (GGPP) are isoprenoid products of
enhanced glomerular production of platelet-derivedthe intracellular mevalonate pathway used for prenylation of
growth factor (PDGF) plays a key role in the pathogene-several low molecular weight G proteins, including Ras. It is
likely that platelet-derived growth factor (PDGF) stimulation sis of proliferative glomerular diseases [5]. It is likely
of mesangial cell proliferation requires prenylated, low molecu- that PDGF stimulation of mesangial cell proliferation
lar weight G proteins. The purpose of this study was to investi- requires prenylated, low molecular weight G proteins.
gate the dependence of platelet-derived growth factor-stimu-
Indeed, other studies have indicated that prenylated Raslated mesangial cell DNA synthesis and cell membrane Ras
is required for PDGF receptor signal transduction [6, 7],incorporation on FPP and GGPP.
and Li et al have recently demonstrated that PDGFMethods. Quiescent human mesangial cells were exposed to
PDGF (25 ng/ml) to stimulate DNA synthesis. Some cells were stimulates mesangial cell Ras activation [3]. Which
also treated with the HMG-CoA reductase inhibitor lovastatin isoprenoids are required for PDGF stimulation of mes-
(2.5 to 10.0 mm), which inhibits isoprenoid synthesis, in the angial cells, however, has not been systematically investi-presence or absence of exogenous FPP or GGPP. DNA synthe-
gated. This is of potential clinical importance, as phar-sis was assessed by thymidine incorporation, and Western blot
macological agents have been, and are being, developedanalysis was used to measure total cell membrane Ras.
Results. Stimulation of mesangial cells with PDGF did not that can inhibit protein prenylation [8, 9]. Such agents
increase total cell membrane Ras. Lovastatin reduced cell could conceivably be beneficial in the treatment of prolif-
membrane Ras, and this was prevented by simultaneous expo- erative glomerular disease. The purpose of this study
sure of mesangial cells to exogenous FPP (2.5 to 10.0 mm) or
was therefore to investigate the dependence of PDGF-GGPP (1 to 5 mm). Lovastatin also reduced PDGF-stimulated
stimulated mesangial cell DNA synthesis and cell mem-mesangial cell DNA synthesis by 90%, and this was completely
brane Ras incorporation on FPP and GGPP.prevented by simultaneous exposure of cells to exogenous
GGPP (1 mm), but not to FPP.
Conclusions. The results of this study suggest that both FPP
METHODSand GGPP can provide for mesangial cell membrane Ras local-
ization and that PDGF-stimulated mesangial cell DNA synthe- DNA synthesis
sis requires the isoprenoid GGPP.
Semiconfluent human mesangial cells were synchro-
nized to quiescence by 72-hour incubation in RPMI 1640
supplemented with 0.5% fetal bovine serum. LovastatinFarnesyl pyrophosphate (FPP) and geranylgeranyl py-
(2.5 or 5.0 mm) was added to some cells during the lastrophosphate (GGPP) are two isoprenoid products of the
16 hours of synchronization. At the end of the synchroni-intracellular mevalonate pathway used for the prenyla-
zation period, the mesangial cells were exposed totion of several low molecular weight G proteins that
PDGF-BB (25 ng/ml) to stimulate DNA synthesis. Lo-are recognized to be important for cell proliferation,
vastatin-pretreated mesangial cells were exposed also toincluding Ras (p21ras), Rho, and Rap [1, 2]. Previous
lovastatin alone (2.5 or 5.0 mm) or to lovastatin together
with either FPP (0.1 to 0.5 mm) or trans-GGPP (0.25 to
1.0 mm). Tritiated thymidine (1 mCi/ml) was added toKey words: isoprenoids, farnesyl pyrophosphate, Ras, lovastatin,
G-proteins, proliferative glomerular disease. all wells, and total tritium incorporation was measured
over a 42-hour period. 1999 by the International Society of Nephrology
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Fig. 1. Western blot analysis of mesangial cell membrane total Ras using pan-Ras primary antibody. (A) Quiescent mesangial cells maintained
in culture medium containing 0.5% fetal bovine serum. (B) Mesangial cells exposed for 24 hours to platelet-derived growth factor (PDGF; 25 ng/
ml); PDGF did not increase the membrane total Ras relative to that in control cells. (C) Lovastatin (10 mm) reduced cell membrane total Ras in
PDGF-stimulated mesangial cells. (D–F) Farnesyl pyrophosphate (FPP) repletion (2.5, 5.0, and 10.0 mm, respectively) restored cell membrane Ras
in lovastatin-treated mesangial cells. (G–I) Geranylgeranyl pyrophosphate (GGPP) repletion (1.0, 2.5, and 5.0 mm, respectively) restored cell
membrane Ras in lovastatin-treated mesangial cells. The results shown are representative of three individual experiments.
Electrophoresis and Western blot analysis PDGF for 24 hours did not increase cell membrane total
Ras (Fig. 1). Lovastatin reduced cell membrane Ras inIn separate experiments, quiescent mesangial cells in
PDGF-treated mesangial cells, and the inhibitory effectculture flasks were exposed to PDGF-BB (25 ng/ml).
of lovastatin on cell membrane Ras incorporation wasLovastatin-pretreated cells were also exposed to lova-
completely prevented by simultaneous exposure of cellsstatin alone (10 mm) or to lovastatin together with either
to exogenous FPP or GGPP (Fig. 1).FPP (2.5 to 10.0 mm) or trans-GGPP (1.0 to 5.0 mm).
After 24 hours of incubation, the media were removed,
DNA synthesisand the cells were washed twice with cold phosphate-
Platelet-derived growth factor caused a marked stimu-buffered saline. The cells were scraped from the flasks,
lation of human mesangial cell DNA synthesis, as as-pelleted, and sonicated in 1.0 ml phosphate-buffered sa-
sessed by tritiated thymidine incorporation. Lovastatinline containing 2 mm ethylenediaminetetraacetic acid
caused a dose-dependent inhibition of PDGF-induced(EDTA) and 1.0 mm Pefabloc. Cell debris was removed,
DNA replication (Fig. 2). Exogenous FPP reversed in aand the cell membranes were collected by centrifugation
dose-dependent manner lovastatin inhibition of DNAat 100,000 3 g for 30 minutes and redissolved by sonica-
synthesis, although the extent of FPP reversal was depen-tion in lysis buffer. Samples (30 to 50 mg) of cell mem-
dent on the degree of lovastatin inhibition (Fig. 2). Exog-brane proteins were subjected to sodium dodecyl sulfate-
enous GGPP also reversed lovastatin inhibition of mes-polyacrylamide gel electrophoresis [10], and proteins
angial cell DNA synthesis in a dose-dependent mannerwere immobilized by electrophoretic transfer to a poly-
(Fig. 2). By contrast to the results with FPP, the extentvinylidene fluoride (PVDF) membrane. The blot was
of GGPP reversal was not dependent on the degree ofincubated with 1 mg purified mouse monoclonal pan-Ras
lovastatin inhibition.antibody (Oncogene) to detect total membrane Ras. A
secondary goat antimouse IgG conjugated with horse-
radish peroxidase and SuperSignal Ultra (Pierce Chemi-
DISCUSSIONcal, Rockford, IL, USA) were used to produce a chemilu-
The results of this study indicate that human mesangialminescent signal that was recorded on X-Omat AR
cells express cell membrane-bound Ras proteins and thatautoradiography film. Images were scanned on a densi-
either FPP or GGPP can permit Ras localization at thetometer, and the specific bands were quantitated using
cell membrane. The results further suggest that PDGFImageQuaNT Software (Molecular Dynamics, Sunny-
stimulation of mesangial cell DNA synthesis requiresvale, CA, USA).
the isoprenoid GGPP. As shown in a previous study
Statistical analysis using the HMG-CoA reductase inhibitor simvastatin
[11], lovastatin in this study caused a dose-related inhibi-Results were expressed as mean 6 sem. The signifi-
tion of PDGF-stimulated mesangial cell DNA synthesis.cance of differences between the means of groups was
At a lovastatin dose (5 mm) that inhibited DNA synthesistested using analysis of variance. Differences were con-
by 90%, the lovastatin inhibition was reversed onlysidered significant for a P of less than 0.05.
slightly by exogenous FPP. By contrast, repletion of lo-
vastatin-treated mesangial cells with exogenous GGPP
RESULTS fully reversed the lovastatin inhibition of DNA synthesis.
Western blot analysis These results therefore suggest that GGPP, rather than
FPP, might be the critical isoprenoid required for PDGF-Quiescent mesangial cells maintained in low-serum
stimulated mesangial cell proliferation.culture medium demonstrated constitutive cell mem-
brane Ras (Fig. 1). The exposure of mesangial cells to These results are also in agreement with recent reports
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Fig. 2. (A) Effects of farnesyl pyrophosphate (FPP) repletion on platelet-derived growth factor (PDGF)-stimulated DNA synthesis (42-hr tritiated
thymidine incorporation) in mesangial cells treated with 2.5 mM (h) or 5.0 mM ( ) lovastatin. DNA synthesis was reduced by approximately 45%
in mesangial cells treated with 2.5 mm lovastatin, and this was prevented in cells exposed simultaneously to 0.5 mm FPP. DNA synthesis was reduced
nearly 90% in mesangial cells treated with 5.0 mm lovastatin, and this was only partially prevented by simultaneous exposure of cells to FPP. The
results indicate mean 6 se of quadruplicate measurements. Data are expressed as a percentage of cpm in control mesangial cells exposed only to
PDGF. (B) Effects of GGPP repletion on PDGF-stimulated DNA synthesis (42-hr tritiated thymidine incorporation) in mesangial cells treated
with 2.5 mm (h) or 5.0 mm ( ) lovastatin. Simultaneous exposure of lovastatin-treated mesangial cells to exogenous GGPP (0.5 to 1.0 mm)
completely prevented the inhibitory effect of lovastatin at either lovastatin dose. The results indicate mean 6 se of quadruplicate measurements.
Data are expressed as a percentage of cpm in control mesangial cells exposed only to PDGF. *P , 0.05 vs. control cells.
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